Who are Mesoblast Limited's main suppliers?

Mesoblast Limited (MESO) key suppliers include: LONZA, Edesa Biotech, Inc., MEOBF. View the full supplier network at chainsifter.com/chain/MESO.

Who are Mesoblast Limited's major customers?

Mesoblast Limited (MESO) key customers include: LONZA-BIOSCIENCE-SINGAPORE-PTE-LTD, UNITED-STATES-THE-GROUP, Edesa Biotech, Inc., MEOBF, Takeda Pharmaceutical Company Limited and 5 more. View the full customer network at chainsifter.com/chain/MESO.

What sector is Mesoblast Limited in?

Mesoblast Limited (MESO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Mesoblast Limited Suppliers, Customers & Supply Chain (MESO)

3Suppliers

10Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Mesoblast Limited (MESO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

1Distinct source URLs

5High confidence

0.748Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Mesoblast Limited Suppliers

Ticker	Name	Confidence	Evidence
LONZA	LONZA	92%	Mesoblast has established a strategic alliance with Lonza, a global leader in biopharmaceutical manufacturing.
EDSA	Edesa Biotech, Inc.	72%	Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…
MEOBF	MEOBF	72%	Reciprocal relationship from MEOBF graph: Reciprocal relationship from MESO graph: Reciprocal relationship from MEOBF graph: Reciprocal relationship from MESO graph: Reciprocal relationship from MEOB…

Mesoblast Limited Customers

Ticker	Name	Confidence	Evidence
LONZA-BIOSCIENCE-SINGAPORE-PTE-LTD	LONZA-BIOSCIENCE-SINGAPORE-PTE-LTD	85%	rs, including the failure to produce sufficient quantities and the inability to produce cells that are equivalent in physical and therapeutic properties as compared to the products produced using our…
UNITED-STATES-THE-GROUP	UNITED-STATES-THE-GROUP	85%	The Group began commercializing Ryoncil ® in the United States for the treatment of pediatric patients with SR-aGvHD in March 2025. The Group's product revenues consist of sales of Ryoncil ® in the U…
EDSA	Edesa Biotech, Inc.	72%	Reciprocal relationship from EDSA graph: Reciprocal relationship from MESO graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary…
MEOBF	MEOBF	72%	Reciprocal relationship from MEOBF graph: Reciprocal relationship from MESO graph: Reciprocal relationship from MEOBF graph: Reciprocal relationship from MESO graph: Reciprocal relationship from MEOB…
TKPHF	Takeda Pharmaceutical Company Limited	72%	agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from MESO graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from MESO graph: agreement to determine if they ar…
CHINA-THE-GROUP	CHINA-THE-GROUP	62%	agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t…
IP-THE-GROUP	IP-THE-GROUP	62%	agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t…
LONZA-WALKERSVILLE-INC	LONZA-WALKERSVILLE-INC	62%	tor the drug’s safety or efficacy. Delays in the REMS approval process could result in delays in the BLA approval process. In addition, as part of the REMS, the FDA could require significant restrict…
TASLY-PHARMACEUTICAL-GROUP	TASLY-PHARMACEUTICAL-GROUP	62%	agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t…

Mesoblast Limited Debt Obligations

Instrument	Description	Confidence	Evidence
MESO-DEBT	Debt stack $135.1M	90%	Market cache reports total debt of $135.1M.

Mesoblast Limited Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Mesoblast Limited.

Mesoblast Limited Ownership

Holder	Name	Confidence	Evidence
MESO-OWNER-49-WEALTH-MANAGEMENT-LLC	49 WEALTH MANAGEMENT, LLC	90%	13F overlay lists 49 WEALTH MANAGEMENT, LLC as top holder; 1 tracked holders.

Mesoblast Limited Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
NVAX	Novavax, Inc.	100.00	2
MRK	Merck & Co., Inc.	100.00	2
JBIO	Jade Biosciences, Inc.	100.00	2
NBIX	Neurocrine Biosciences, Inc.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
MIRM	Mirum Pharmaceuticals, Inc.	100.00	2
CMMB	Chemomab Therapeutics Ltd.	100.00	2
DNLI	Denali Therapeutics Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	1	['customer', 'supplier']
TKPHF	Takeda Pharmaceutical Company Limited	100.00	1	['customer']
ACRS	Aclaris Therapeutics, Inc.	100.00	2
MEOBF	MESOBLAST LTD	100.00	1	['customer', 'supplier']
CLLS	Cellectis S.A.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
INCY	Incyte Corporation	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
TAK	Takeda Pharmaceutical Company Limited	100.00	2

Mesoblast Limited Supply Chain